Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Operating Expenses (2016 - 2025)

Editas Medicine (EDIT) has disclosed Operating Expenses for 11 consecutive years, with $32.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses fell 51.18% to $32.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $245.2 million, a 15.52% decrease, with the full-year FY2024 number at $283.5 million, up 14.62% from a year prior.
  • Operating Expenses was $32.1 million for Q3 2025 at Editas Medicine, down from $55.1 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $84.0 million in Q4 2023 to a low of $32.1 million in Q3 2025.
  • A 5-year average of $61.2 million and a median of $60.6 million in 2022 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: skyrocketed 54.14% in 2024, then tumbled 51.18% in 2025.
  • Editas Medicine's Operating Expenses stood at $54.1 million in 2021, then rose by 29.41% to $70.0 million in 2022, then rose by 20.05% to $84.0 million in 2023, then decreased by 8.11% to $77.2 million in 2024, then plummeted by 58.43% to $32.1 million in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Operating Expenses are $32.1 million (Q3 2025), $55.1 million (Q2 2025), and $80.8 million (Q1 2025).